Natriuretic Peptide Concentrations of B-type (BNP) During Anesthesia in Patients Previously Sensitized to Anthracyclines
- Sponsor
- Institut Bergonié
- Study ID
- NCT01754597
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Dosage of B-type natriuretic peptide (NT-proBNP) — OTHERNT-proBNP concentration assessed at the following time points : * T0: before induction of general anesthesia, NT-proBNP measurement * T1: 30 minutes after induction of general anesthesia * T2: at the end of the procedure * T3: in the postoperative period, 6 hours after the end of the procedure * T4: in the postoperative period, 24 hours after the end of the procedure
Study Details
The cardiotoxicity of anthracyclines chemotherapy remains a major problem, despite clinical and echocardiographic monitoring. In the case of treatment for breast cancer, surgery requiring general anesthesia may follow chemotherapy. Although a possible interaction between general anesthetics and anthracyclines on systolic function is only rarely mentioned, some cases of heart failure and / or conduction disturbances peranesthésique were observed in patients treated or previously treated with anthracyclines. The determination of concentration of BNP is a diagnostic tool used in the detection of heart failure and acute coronary syndromes. The question of a possible synergism between cardiotoxic anthracyclines and anesthetic agents arises. Given its minimally invasive nature and its diagnostic value, the BNP assay might thus allow to highlight a possible subclinical deficiency. To our knowledge, there is very little data regarding a possible synergism between cardiotoxic anthracyclines and anesthetic agents.
Key Dates
- Start date
- Sep 30, 2009
- Status verified
- Sep 2025
- Primary completion
- Dec 31, 2012
- Completion
- Dec 31, 2012
Study Design
- Enrollment
- 54 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- OTHER
Arms
- Other: Participants not previously treated with anthracyclinesNo anthracycline treatment in the 6 months prior to inclusion.
- Other: Participants previously treated with anthracyclines
Primary Outcome Measure
Pre-operative Concentration of NT-proBNP [ Time Frame: Before breast surgery ]
Related Studies
- Collection of Blood From Patients With CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Harvesting Cells for Experimental Cancer TreatmentsEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
- High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast CancerRecruiting · Carol Fabian, MD · Kansas City, Kansas
- Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland